BCL2L1 and plasma cell myeloma: On the other hand, in myeloma cells, the binding of BIM to BCL-XL and BCL-2, but not the expression pattern, is associated with sensitivity to ABT-737 (BCL-2/BCL-XL/BCL-W inhibitor) [97].